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Abstract
 Purpose: MulƟ drug-resistant tuberculosis (MDR-TB) paƟ ents have few adverse 
eff ects due to treatment regimens, including psychological side eff ects that play 
an important role in the successful MDR-TB management. This study was aimed 
to idenƟ fy MDR-TB paƟ ents’ challenges within the context of psychological 
issues and to determine suitable intervenƟ on to address psychological problems 
in MDR-TB paƟ ents. Method: We conducted a systemaƟ c review as PRISMA 
guidelines using databases PubMed, ProQuest, ScienceDirect, Scopus, and 
Portal Garuda to search for all related arƟ cles. From studies idenƟ fi ed, 10 
were included in the fi nal analysis. Results: It was found that all studies have 
documented a range of psychological challenges faced by MDR-TB paƟ ents 
that were depression, anxiety, suicidal tendencies and common issues reported 
in the studies. Conclusion: There were three main strategies that can be 
implemented in every country to address MDR-TB adverse eff ect and scale-
up MDR-TB treatment effi  cacy. These strategies require high levels of support 
from health workers and family member which has an important role in the 
treatment process.
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 INTRODUCTION
 The emergence of Tuberculosis (TB) with antimicrobial 
resistance is considered as a new threat to world health 
problems. World Health Organization (WHO) in 2017 
estimated that the number of Multidrug-resistant 
tuberculosis (MDR-TB) at 558 000 new cases, of which 
240 000 deaths were due to MDR-TB. An estimated case 
of MDRT-TB came from 4.1% of new TB cases and 19% of 
previously treated TB cases [1]. MDR-TB is the condition 
where TB caused by Mycobacterium Tuberculosis infection 
did not respond at least to the two most effective first-line 
anti-tuberculosis drugs that are isoniazid and rifampicin 
[2]. The presence of drug resistance is attributed to poor 
treatment management [3]. The success rate of treatment 
was still far from the target which should be 75% or 
higher, yet only 52% MDR-TB was successfully treated 
[4]. Most MDR-TB patients remain incompletely treated 
due to the long duration of treatment where duration is 
often 18 - 24 months or longer [3–5]. Besides long-term 
treatment is needed, inadequate supply and quality of 
drugs, bacterial factors, and the patient’s own condition 
also give influence. Aggravated by the cost of second-line 
anti-tuberculosis drugs tend to be expensive and have 
severe drug side effects [6].
 Living with long-term treatment needs, MDR-TB 
patients will not get only unfavorable effects on the 
physical aspects. These effects are manifested bilateral 
deafness, tinnitus, nausea, weakness and pain in the 
shoulder and limbs, back spasms, sensory neuropathy, 
persistent loss of bladder and bowel control [6–9]. 
Furthermore, psychological issues often play an important 
role in successful MDR-TB control. The challenge is 
compounded by MDR-TB drugs regimen and due to 
prolonged treatment which can develop into psychological 
distress and a number of psychiatric illnesses such as 
anxiety, depressive disorders, even in more severe cases 
the risk of suicide can occur [10–12]. Comorbidities of 
physical and mental disorder lead to synergistically impair 
medication and treatment adherence. Psychological 
support interventions are needed for patients with MDR-
TB(13). Consolidated evidence about the psychological 
problems among MDR-TB patients is limited. To address 
the evidence gap, we aimed to review psychological 
issues that must be faced by MDR-TB patients and to 
address these problems with related interventions and 
to minimize the likelihood of withdrawal medication.
 
METHOD
This systematic review was conducted according to 
the PRISMA (Preferred Reporting Items for Systematic 
Reviews and Meta-analyses) statement [6,13]. A systematic 
search of relevant articles in PubMed, ProQuest, 
ScienceDirect, Scopus, and Portal Garuda was used 
to identify all published articles using the following 
keywords: multidrug-resistant tuberculosis, tuberculosis 
drug resistance, mental health, mental disorders, and 
psychological factors.
 Eligible studies were included if they met the 
following criteria were  all cultures confirmed in adult 
patients with MDR-TB who either are undergoing or have 
undergone treatment, the articles published from January 
1st, 2013 to October 1st, 2018, the English and Bahasa 
articles,  all articles identified by each  reviewer base on 
full text review, and the provided full search strategy. The 
exclusion criteria were standardized first-line therapy in 
the treatment protocol.
 The search strategy was used in this review. Titles 
and abstracts were excluded if they are irrelevant to this 
review. Data collected included reference, study location, 
year, method, and findings. We defined psychological 
distress as any adverse effect on the mental status of the 
MDR-TB patients resulting from either the illness itself or 
treatment undertaken. When available in original studies, 
the association between MDR-TB and our outcomes of 
interest were extracted, along with their 95% confidence 
interval (95%CI). Thematic synthesis method for 
extracting related pieces of evidence was systematically 
transformed into a descriptive review using a narrative 
approach.
 Due to the multiple research methodologies used, 
we used the Critical Appraisal Skills Programme (CASP) 
checklist to rate the quality of each research using a 
narrative approach. We rated the quality of research using 
components of CASP designed to be used for each of the 
research methods. According to the needs of appraisal 
tools, we used tools for systematic reviews, Qualitative 
studies, cohort studies, and case-control studies. The CASP 
included 10 until 12 questions that help us to analyze those 
questions divided into 3 sections, they are,  the validity 




Of the publications, 356 identified, 346 were excluded 
because they did not meet eligibility inclusion criteria. 
Among the 10 studies selected were conducted in different 
countries including Mexico in 2013 [6], India in 2013 
[10,14,15], Pakistan in 2016 [10,14], Nepal in 2016 [10], 
South Korea in 2017 [8], India in 2017 [12], Indonesia in 
2017 [12,16], and Serbia in 2018 [9]. The remaining two 
studies have not clearly mentioned the study setting [5,17]. 
Of the 10 studies, five were original studies which of three 
were qualitative methodology, one study was conducted 
retrospective and consecutive review based on medical 
records [8,16], one study was the case report, and one 
study was case-control [16]. All the 10 studies were focused 
on psychological issues faced by MDR-TB patients.
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 Four studies identified the psychological issues 
faced by MDR-TB patients caused by the adverse effect 
of second-line drugs [8,12,15,17]. It was reported that 
cycloserine regimen induced psychiatric symptoms such 
as depression, anxiety, consciousness, disorientation to 
time and place, experiencing perceptual disturbances in 
the form of visual hallucinations as well-known delirium, 
and even worse severe suicidal tendencies [12]. 
 O ne study has reported that depression as primarily 
side effects was associated with cycloserine. Other 
studies found half of the MDR-TB patients had one or 
more comorbid conditions, including depression that 
often occurs while undergoing treatment. Even in one 
study reported that the number of patient depression 
due to second-line drug effects was very high [17]. Other 
than that some psychiatric illnesses which if not treated 
properly were resulting in worse outcomes as though 
suicide incidents, also increase the risk of morbidity 
and mortality [16,17]. Despite several studies the scarce 
sources stated that the MDR-TB drugs lead to suicide 
[17]. Measly incident does not rule out the possibility of 
subsequent cases. MDR-TB patients with neuropsychiatric 
side effects have been found to have significantly worse 
outcomes and a higher likelihood of death [5,10].
F ive studies identified the psychological issues associated 
with prolonged treatment [5,6,10,14,18]. Whether as 
consequences of drug side effects or due to prolonged 
treatment, psychological distress comorbid are frequently 
found in MDR-TB patients [5]. Psychological distress tends 
to be a debilitating treatment that manifests with disordered 
in the areas of emotions, perceptions, thinking, and memory 
and have no established biological basis [17]. The magnitude 
of psychological distress significantly associated with the 
period of treatment. A positive association between patients 
administered within 1-2 months of treatment initiation and 
high psychological distress incidence rate has previously 
been reported by a study conducted elsewhere. Any study 
notified that most emotions often expressed by MDR-TB 
when initially diagnosed with the disease was hopelessness 
and fear feelings [12]. 
T hree studies identified regarding feelings reflect 
the MDR-TB patient’s opinion about the treatment that 
is final option for them [6,14,15]. These feelings reflect 
the MDR-TB patient’s opinion about the treatment that 
is final option for them [10,15]. Much perceived fear of 
MDR-TB treatment ineffectiveness offered them cure 
for their illness. The level of patient reliance on the 
effectiveness of the treatment may influence their sense 
of hope and belief in being cured [10]. Compounded 
by witness other patients dying from MDR-TB generate 
difficulties to remain optimistic. The MDR-TB treatment 
challenges that are frequently observed as follows patients 
complaint regarding taking too many medicines at one 
time, having to undergo length daily treatment, painful 
F ig 1. Flow diagram indicating the process of selecting the studies
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injections, and awful taste of medicine [8,17]. Which are 
not a few patients who experience these treatments feel 
very stressful and have developed anxiety immediately 
upon learning about their disease [6]. Most of the patients 
who remained sick more than one year after the diagnosis 
of MDR-TB had received multiple incidental of treatment 
and complicated pathways of care could be possible 
reasons for significantly lower mental health. Especially 
for patients who previously treated and find treatment 
failure was mostly horrified and lacked any faith to 
cure their disease [17]. The majority of MDR-TB patients 
generally lacked knowledge whether it’s about the disease 
itself, treatment, or side effects, which of fuelled patient’s 
anxieties. Inadequate information meant whether 
patients must to do, whether they should seek providers 
help, whether their conditions need to be consulted, and 
whether how to address their difficulties in treatment 
related to psychological distress.
 DISCUSSIONS
The research on psychological issues in MDR-TB 
patients is still rare, however robust research regarding 
these issues is extremely important for the successful 
MDR-TB management. This review focuses on the 
various psychological distress due to the disease itself 
as well as the treatment side effects. Some studies 
reported psychological distress were the second most 
common reason leading to treatment withdrawal [8]. The 
psychological distress also significantly inhibit adherence 
of MDR-TB treatment where the problem of medication 
adherence is the most challenging factor which affected 
discontinued treatment [16,19]. The fact that treatment 
interruption can be dangerous for the patients also 
compromises treatment efficacy which of them may 
remain infectious, dealing with mortality related TB and 
increased possibilities of XDR-TB [18]. 
T reatment experience faced by MDR-TB patients 
reflected complex interplay adverse effects, not only 
physical side effects, but also psychological challenges. 
Once initiated on treatment, the patient needed to 
adjust to all medication difficulties which there were 
no other treatments and no way out [14]. The following 
were possible adverse effects of MDR-TB drugs that are 
nausea, vomiting, bilateral deafness, tinnitus, weakness 
and pain in the shoulder and limbs, also psychological 
distress such as anxiety, depression, psychosis and suicidal 
tendencies [8,10,14,16]. The MDR-TB drug side-effects 
were perceived as bad as or worse than the illness itself 
[15]. The second line drug regimens used in the MDR-
TB treatment are more severe than the first-line drugs 
including neuropsychiatric effects. Compared to other 
second-line drugs, cycloserine has a higher number of 
neurologic side effects than others, however the effects 
of cycloserine particularly dose-related [11].
O ne of the causes of high rates of non-adherence and 
loss to follow-up in MDR-TB treatment may be due to 
undiagnosed and comorbid psychological distress that is 
untreated [5]. Psychological distress symptoms are often 
abandoned and not considered as a big deal by MDR-TB 
patients, even when they noticed these symptoms they 
prefer to be reticent to disclose which causes this issue 
is frequently overlooked by clinicians and policymakers 
[5]. Furthermore, another challenge encountered was 
the support tool to diagnose the psychological distress of 
MDR-TB patients and provide suitable interventions [20]. 
The WHO guidelines for the programmatic management 
of drug-resistant tuberculosis illustrated the assessment 
for patient’s psychological conditions with routinely 
questions whether the patients of MDR-TB ever thought 
of committing suicide and other psychological distress 
which might exist related to their illness and treatment 
of the disease [5,21].
Strategies for managing the possibility of ineffective 
treatment in terms of psychological distress require 
special attention. The first thing to do begins with the 
knowledge that every stakeholder needs to have regarding 
MDR-TB disease, treatment, also presence of drugs side 
effects [5]. The intended stakeholders including MDR-TB 
patients, clinicians, and program providers that involved 
in MDR-TB treatment should be educated to identify the 
relevant symptoms associated with adverse effect due to 
treatment which can increase awareness of psychological 
distress among MDR-TB patients [21,22].  Specifically 
to address MDR-TB outpatient treatment issues, clear 
information suggested the provision of drugs for patients 
also their family members to take at home were provided 
by health workers [22]. Target information including 
patient’s family members would assist to address drug 
non-adherence also stigma issues that have sprung up in 
the community. 
As a caretaker, the family members are the key 
to supporting patients at this time which has been 
acknowledged for their important role in the treatment 
process [23]. Especially for parents and wives or husband 
were fully involved in the day of the patient’s care 
belonging accompanying patients, facilitating discussions, 
and providing psychological support [10].
 The second strategies according to the WHO guidelines 
suggested that mandatory programs that need to be 
followed by MDR-TB patients with psychological distress 
symptoms are individual counseling and group therapies 
[5,24]. Patients in denial terms and unable to absorb 
information will be more suitable for discussion and 
sharing their experiences [10,22]. The counseling and 
group therapy were aimed to minimize asymmetric 
information where communication limited to one-way 
and not patient-centered, with a little consideration 
of information patients’ needs [22]. With discussion, 
especially during group therapy consists of fellow MDR-
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 T able 1 Studies on psychological issues of MDR-TB patients
Reference Year Place Objective Method Pop Findings
Meghan D. 
Morris et al
2013 Mexico psychological 
impacts of  MDR-
TB treatment
Qualitative 12 Patients notified their feeling distressed and 








Qualitative 12 Patients voiced concern about adverse effects 




2016 Pakistan Effects MDR-TB 
treatment seen 
through patient’s 
quality of  life
Prospective 
follow-up
81 Patients with MDR-TB have been reported 
had lower scores on psychological health, 
an d indication of  more mental distress and 




2016  Psychological 








 Neurologic side effects included depression, 
anxiety, convulsions, consciousness, psychosis, 
and suicide issues of  MDR-TB patients also 
the importance of  psychological intervention 
their offer
Debaleena Das 2017 India Adverse effect of  
cycloserine
Case report 1 Cycloserine in psychotic, manic or depressive 
patients suffering from MDR-TB may impose 











Qualitative 15 Patient reported anxiety and depression. 
Developing intervention through improving 
communication skill of  health worker, 
involvement of  family members, and assessing 
psychosocial issues as part intervention 
evaluation
Tae Won Yang, 
MD et al
2017 South Korea Psychological 
adverse effects of  
MDR-TB drugs
Retrospective of  
medical records
256 Among adverse effects of  MDR-TB 
treatment, psychological disorders symptoms 
such as depression, anxiety, nightmares, 
and psychotic have positive association with 
second line anti tuberculosis drug
LinaAlfiyani 
et al
2017 Indonesia Factors treatment 
adherence due to 
biopsychosocial 
issues faced by 
MDR-TB patients
Case-control 304 Drug taking adherence significantly affected 
by depression, support of  family members 
intervention to address depression and 
treatment adherence 








 Psychosocial impact experience of  people with 
MDR-TB often lead to depression and anxiety, 
social stigma, and psychiatric illness due to 
regimen MDR-TB  treatment
StosicMaja et al 2018 Serbia Risk factors 
among MDR-TB 
patients
Case-control 124 Mental health, defaulting of  treatment, 
sadness, and using sedatives significantly 
associated with MDR-TB patients experienced
TB sufferers, patients openly and freely express their 
feelings regarding their illness and especially on drugs 
adverse effect [6]. As well as improve of properly design 
communication to supporting MDR-TB management.
 Attributed to the high number of psychological 
distress during MDR-TB treatment, the last strategy has 
been directly handled by specialist physicians. Continuing 
the prescribed treatment regimen with additional 
medication is most appropriate for patients who are 
experiencing mild adverse effects [21]. The psychiatric 
adverse effect that has been reported primarily associated 
with MDRT-TB medication which initially used with an 
antidepressant, antipsychotic, or anticonvulsant therapy 
[24]. Giving pyridoxine also known as vitamin B6 to 
patients who consume cycloserine or terizidone would 
prevent psychiatric adverse effects. In the worst case 
where additional medication not going well to manage 
psychiatric side effects, the intended drugs need to be 
replaced or suspended. Still, replacement drugs may not 
be available in MDR-TB patients likewise suspending the 
medication will reduce treatment regimen effectiveness. 
Suggested strategies for emergency psychiatric cases 
are stopping the suspected drug for a short period 
of time around 1- 4 weeks until the patient is stable. 
Another method is reducing treatment regimen without 
compromise [8,23,25]. To eliminate or lessen the 
Berita Kedokteran Masyarakat, Volume 35 No. 4 Tahun 2019
160 
psychiatric adverse effect of cycloserine and ethionamide, 
commonly reducing to 500 mg daily. It is recommended 
to improve medication adherence also avoid drug 
withdrawal in MDR-TB patients [21].
 
 LIMITATIONS
 This review has some limitations. Firstly, there are still 
a small number of study which focuses on the psychology 
of patients with MDR-TB. Secondly, the study method 
which is identified did not focus one type because of the 
limitation of appropriate articles with inclusion criteria.
 CONCLUSION
 The emergence of psychological distress in MDR-TB 
patients due to the disease itself as well as the side effects 
of treatment needs special attention. Undiagnosed and 
untreated psychological distresses in MDR-TB patients’ 
cases are highly prevalent whereas it can be dangerous for 
both the patients and the treatment efficacy. The various 
psychological adverse effects of MDR-TB treatment 
directly leads to medication non-adherence which may 
then be withdrawn. The assessing psychological side 
effects were aimed to increase awareness and offer 
the best intervention option for MDR-TB patients. The 
appropriate intervention to address drug’ side effects is 
the key for the success of MDR-TB management.
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